IOL Chemicals & Pharmaceuticals Ltd

IOL Chemicals Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

IOL Chemicals & Pharmaceuticals Ltd

₹ 376 0.60%
18 May - close price
iolcp.com BSE: 524164 NSE: IOLCP
About

IOL Chemicals & Pharmaceuticals Ltd is a leading pharmaceutical (APIs) company and is a significant player in the specialty chemicals space. It serves the domestic and export market.[1]

It is the largest player of Ibuprofen (pain killer) globally with a world market share of 35%.[2]

Key Points

Largest Producer of Ibuprofen
It is the largest producer of Ibuprofen (12000 TPA) and the only company worldwide being backward integrated with ~35% Global share. It is the largest producer of Ethyl Acetate at Single Location in India and also 2nd largest producer of Iso Butyl Benzene (IBB) with ~30% Global share. [1]

Website BSE NSE
  • Market Cap ₹ 2,208 Cr.
  • Current Price ₹ 376
  • High / Low ₹ 536 / 350
  • Stock P/E 16.3
  • Book Value ₹ 274
  • Dividend Yield 1.33 %
  • ROCE 12.3 %
  • ROE 8.69 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company has reduced debt.
  • Company is almost debt free.
  • Company has been maintaining a healthy dividend payout of 17.5%

Cons

  • The company has delivered a poor sales growth of 4.82% over past five years.
  • Company has a low return on equity of 10.4% over last 3 years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024
460 519 538 555 572 565 541 523 587 563 545 520 504
349 408 494 496 529 509 510 480 491 490 481 476 454
Operating Profit 111 110 44 59 43 56 32 43 96 73 64 44 50
OPM % 24% 21% 8% 11% 8% 10% 6% 8% 16% 13% 12% 9% 10%
6 -8 11 9 7 5 5 7 9 7 7 8 8
Interest 1 2 2 2 2 3 4 5 5 4 4 4 3
Depreciation 10 10 11 11 11 11 11 12 12 14 16 16 16
Profit before tax 106 90 42 55 37 47 22 33 88 62 51 32 38
Tax % 29% 25% 26% 27% 24% 25% 28% 27% 25% 25% 26% 28% 25%
75 67 31 40 28 35 16 24 65 46 38 23 28
EPS in Rs 12.82 11.41 5.25 6.83 4.73 5.94 2.67 4.11 11.12 7.87 6.44 3.96 4.80
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
482 564 385 580 711 983 1,685 1,894 1,967 2,184 2,217 2,133
392 468 373 529 608 863 1,276 1,321 1,375 1,927 1,990 1,901
Operating Profit 89 96 11 51 102 120 410 574 592 257 227 232
OPM % 18% 17% 3% 9% 14% 12% 24% 30% 30% 12% 10% 11%
3 1 1 1 1 6 10 16 24 17 25 30
Interest 57 60 59 61 68 64 51 21 6 8 16 16
Depreciation 31 32 29 30 30 30 32 36 39 43 46 63
Profit before tax 3 5 -75 -39 6 31 336 533 571 223 189 183
Tax % 46% 35% 12% -4% 21% 12% 30% 32% 22% 26% 26% 26%
2 3 -67 -40 5 28 237 361 445 166 140 135
EPS in Rs 0.61 1.15 -13.99 -7.12 0.83 4.93 41.61 63.51 75.73 28.22 23.84 23.07
Dividend Payout % 0% 0% 0% 0% 0% 0% 0% 5% 8% 14% 17% 22%
Compounded Sales Growth
10 Years: 14%
5 Years: 5%
3 Years: 3%
TTM: -4%
Compounded Profit Growth
10 Years: 45%
5 Years: -11%
3 Years: -33%
TTM: -3%
Stock Price CAGR
10 Years: 28%
5 Years: 16%
3 Years: -15%
1 Year: -15%
Return on Equity
10 Years: 20%
5 Years: 21%
3 Years: 10%
Last Year: 9%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity Capital 26 29 48 56 56 56 57 57 59 59 59 59
Reserves 142 160 154 129 132 160 408 747 1,202 1,332 1,448 1,553
Preference Capital 5 20 0 0 0 0 0 0 0 0 0
400 357 400 453 447 422 284 59 3 44 80 33
159 195 100 135 182 214 193 306 347 526 434 600
Total Liabilities 727 741 702 772 817 852 942 1,170 1,610 1,960 2,021 2,244
430 411 403 400 374 406 412 469 512 561 751 934
CWIP 32 33 4 4 21 7 27 19 48 105 90 100
Investments 0 0 0 0 0 0 0 0 1 2 20 21
265 297 295 369 422 439 503 682 1,048 1,292 1,159 1,190
Total Assets 727 741 702 772 817 852 942 1,170 1,610 1,960 2,021 2,244

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
53 78 -47 18 83 120 273 471 380 91 123 291
-18 -12 -5 -27 -23 -50 -63 -184 -317 -121 -119 -192
-32 -66 50 9 -60 -70 -197 -272 -58 -2 -4 -92
Net Cash Flow 3 1 -2 -0 1 -1 13 15 4 -31 -0 7

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Debtor Days 27 32 31 55 58 54 43 52 56 79 83 81
Inventory Days 199 190 279 201 201 109 66 64 98 95 77 111
Days Payable 116 119 92 102 115 83 42 62 79 95 74 123
Cash Conversion Cycle 110 103 218 154 144 80 67 55 74 79 86 69
Working Capital Days 82 58 173 125 108 73 57 57 66 78 86 77
ROCE % 11% 11% -3% 4% 12% 15% 56% 69% 54% 18% 14%

Shareholding Pattern

Numbers in percentages

4 Recently
Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024
43.69% 43.69% 43.69% 43.69% 43.69% 43.69% 43.69% 48.19% 48.19% 48.19% 48.19% 48.19%
5.05% 2.76% 3.03% 3.14% 2.50% 2.41% 2.37% 2.43% 3.54% 2.33% 2.18% 1.40%
0.04% 0.36% 0.51% 0.04% 0.04% 0.05% 0.16% 0.23% 0.25% 0.35% 0.36% 0.29%
51.21% 53.18% 52.77% 53.13% 53.77% 53.84% 53.78% 49.15% 48.02% 49.12% 49.27% 50.11%
No. of Shareholders 1,27,8931,42,0221,45,0411,46,4371,48,9071,45,6921,43,3271,40,1771,26,0041,35,3971,34,2351,30,003

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls